Breast Cancer

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

When imagining a champion of change, one can easily point to Laura J. van ’t Veer, PhD, the 2020 Giants of Cancer Care® award winner in Cancer Diagnostics, as a prime example.

Extended adjuvant endocrine therapy via intermittent administration of letrozole did not improve disease-free survival vs continuous use in postmenopausal patients with hormone receptor–positive breast cancer, but represents a valid approach for those who require or prefer a treatment interruption.

An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.

Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.